Health Technology
Astellas Pharma, Inc.
- 1,441.00 JPY
- -13.00
- -0.89%
Japan
Aug 20, 2019Ticker
TKS(4503)Prev. close
1,454Market cap (JPY)
2,746.34BMarket cap (USD)
25,829.75MShares
1,888.82M
In the news
- China's big data draws Big Pharma Aug 1, 2019
- Drugmakers tap cutting-edge tech to fight pollen allergies Mar 14, 2019
- China extends drug patents to 25 years May 16, 2018
- Takeda-Shire deal shows it's US or bust for Japanese drugmakers May 10, 2018
- Goldman and Nomura lead all-star team behind Takeda-Shire deal May 10, 2018 See more articles on Astellas Pharma, Inc.
Business Summary
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
Financial Highlights
| Mar 2019 | JPY | USD |
| Revenue | 1,306.34B | 11,780.07M |
| Gross Profit | 979,086M | 8,828.97M |
| Operating income | 280,141M | 2,526.19M |
| Income before tax | 248,967M | 2,245.07M |
| Net income | 222,265M | 2,004.28M |
| EBITDA | 343,599M | 3,098.42M |
| Diluted EPS | 114.94 | 1.03 |
| Dividends Per Share | 38 | 0.34 |
| Total Assets | 1,897.64B | 17,144.58M |
| Total liabilities | 639,252M | 5,775.41M |
| Total equity | 1,258.39B | 11,369.16M |
| Operating cash flow | 261,428M | 2,357.44M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 1,247.25B | 1,372.70B | 1,311.66B | 1,300.31B | 1,306.34B |
| Gross Profit | 875,398M | 994,723M | 955,325M | 970,228M | 979,086M |
| Operating income | 216,283M | 270,577M | 276,419M | 271,241M | 280,141M |
| Income before tax | 189,683M | 261,770M | 281,769M | 218,113M | 248,967M |
| Net income | 135,856M | 193,687M | 218,701M | 164,679M | 222,265M |
| EBITDA | 281,757M | 339,765M | 340,210M | 336,104M | 343,599M |
| Diluted EPS | 61.40 | 89.62 | 103.55 | 81.02 | 114.94 |
| Dividends Per Share | 30 | 32 | 34 | 36 | 38 |
| Total Assets | 1,793.57B | 1,799.33B | 1,814.07B | 1,858.20B | 1,897.64B |
| Total liabilities | 475,662M | 540,129M | 540,614M | 583,608M | 639,252M |
| Total equity | 1,317.91B | 1,259.20B | 1,271.81B | 1,268.28B | 1,258.39B |
| Operating cash flow | 189,977M | 316,534M | 237,230M | 314,463M | 261,428M |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 11,353.53M | 11,431.18M | 12,112.80M | 11,732.27M | 11,780.07M |
| Gross Profit | 7,968.55M | 8,283.53M | 8,822.11M | 8,754.00M | 8,828.97M |
| Operating income | 1,968.77M | 2,253.22M | 2,552.63M | 2,447.30M | 2,526.19M |
| Income before tax | 1,726.64M | 2,179.88M | 2,602.04M | 1,967.95M | 2,245.07M |
| Net income | 1,236.66M | 1,612.92M | 2,019.63M | 1,485.83M | 2,004.28M |
| EBITDA | 2,564.77M | 2,829.38M | 3,141.72M | 3,032.54M | 3,098.42M |
| Diluted EPS | 0.55 | 0.74 | 0.95 | 0.73 | 1.03 |
| Dividends Per Share | 0.27 | 0.26 | 0.31 | 0.32 | 0.34 |
| Total Assets | 14,955.82M | 16,009.05M | 16,279.92M | 17,472.54M | 17,144.58M |
| Total liabilities | 3,966.32M | 4,805.63M | 4,851.60M | 5,487.61M | 5,775.41M |
| Total equity | 10,989.50M | 11,203.42M | 11,413.53M | 11,925.61M | 11,369.16M |
| Operating cash flow | 1,729.31M | 2,635.93M | 2,190.74M | 2,837.28M | 2,357.44M |
Valuation Measures
| Mar 2019 | |
| PER | 14.41 |
| ROA | 11.83% |
| ROE | 17.59% |
| Operating margin | 21.44% |
| Profit margin | 17.01% |
Key executives
- President, CEO & Representative Director: Kenji Yasukawa
- Chief Financial Officer: Chikashi Takeda
- SVP, Head-Innovation & New Technologies: Michael Rafa
- General Manager-Pharmaceutical Technology: Mitsunori Matsuda
- Executive Vice President & General Counsel: Linda Friedman
Shareholders
- Nomura Asset Management Co., Ltd. (5.2%)
- Nippon Life Insurance Co. (3.4%)
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.9%)
- Nikko Asset Management Co., Ltd. (2.9%)
- The Vanguard Group, Inc. (2.6%)
- Daiwa Asset Management Co. Ltd. (2.4%)
- BlackRock Fund Advisors (1.7%)
- Norges Bank Investment Management (1.7%)
- APG Asset Management NV (1.4%)
- Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (1.2%)
Contact Details
- Website:http://www.astellas.com
- Address: 2-5-1 Nihonbashi-Honcho, Chuo-Ku, Tokyo, 103-8411, Japan
- Phone: +81.3.3244.3000
Related Companies
- Astellas Pharma, Inc. /Agensys Research Facilities/
- Astellas Pharma, Inc. /16 Long Listed Products/
- Astellas Farma Colombia
- Astellas Pharma Director Incentive Plan
- Quethera Ltd.
- PT Astellas Pharma Indonesia
- Astellas Pharma ZAO
- Astellas Pharma ilac Ticaret ve Sanayi AS
- Astellas Pharma Hong Kong Co. Ltd.
- Astellas Pharma India Pvt Ltd.
- Astellas Pharma Thailand Co. Ltd.
- Astellas Pharma Australia Pty Ltd.
- Astellas Pharma Singapore Pte Ltd.
- Astellas Pharma Tech Co., Ltd.
- Mitobridge, Inc.
- Astellas Pharma China, Inc.
- Perseid Therapeutics LLC
- GPDC Partnership
- Astellas Pharma Philippines, Inc.
- Astellas Pharma Co. Ltd.
- Astellas Pharma Canada, Inc.
- Fujisawa Taiwan Co. Ltd.
- Astellas Pharma SARL
- Astellas Pharma Netherlands
- Yamanouchi Health & Beauty Co. Ltd.
- Yabrofarma Lda.
- Fujisawa Ireland Ltd.
- Astellas Pharma Korea, Inc.
- Yamanouchi USA, Inc.
- Astellas Pharma SP zoo
Competitors
- AstraZeneca PLC
- Hanmi Pharmaceutical Co., Ltd.
- BioLineRX Ltd.
- Regeneron Pharmaceuticals, Inc.
- Ipsen SA
- AbClon, Inc.
- Bicycle Therapeutics Plc Sponsored ADR
- Coland Holdings Ltd.
- Ionis Pharmaceuticals, Inc.
- Pieris Pharmaceuticals, Inc.
- Mirati Therapeutics Inc.
- Antares Pharma, Inc.
- Trovagene, Inc.
- Constellation Pharmaceuticals, Inc.
- Sophiris Bio Inc.
- Urovant Sciences Ltd.
- Agios Pharmaceuticals, Inc.
- Matinas BioPharma Holdings, Inc.
- Akebia Therapeutics, Inc.
- Cidara Therapeutics, Inc.
- GlycoMimetics, Inc.
- Synthetic Biologics, Inc.
- Xenon Pharmaceuticals Inc.
- Mersana Therapeutics, Inc.
- Oncternal Therapeutics, Inc.
- ImmunoGen, Inc.
- Kura Oncology, Inc.
- Five Prime Therapeutics, Inc.
- Agenus Inc.
- Athersys, Inc.
Copyright © 2019 FactSet Research Systems Inc. All rights reserved.
Last Updated on 20 Aug, 2019